Immunotherapy has brought promising breakthroughs to several types of cancer. Cervical cancer has a relatively large number of mutations (gene changes), which may make it more sensitive to immunotherapy drugs and may apply immunotherapy to cervical cancer.
A number of clinical trials are in full swing, and the researchers recently summarized a phase II trial of single drug nivolumab (Opdivo) for recurrent cervical cancer. Among the 24 patients: 19 had cervical cancer, 5 had vaginal cancer, and 26% of cervical cancer patients responded to the drug, which is an encouraging result.
Researchers will continue to improve the single-drug program through further trials, but are also pursuing another approach: combination trials. Studies using single-agent immunotherapy with drugs such as pembrolizumab (Keytruda) or nivolumab show that 15% -25% of patients are active, but the remaining patients are inactive, and there is much room for improvement. For this reason, the researchers are more focused on combined trials of cervical cancer.
Tá turgnamh ar bun chun an druga imdhíteiripe atezolizumab (Tecentriq) a phéireáil leis an ngníomhaire frith-angiogenic bevacizumab, a choisceann cealla ailse ó shoithí fola nua a fhoirmiú a chaithfidh fás. Is druga gníomhach é Bevacizumab i gcoinne ailse cheirbheacs, agus tá sonraí réamhchliniciúla ann ar féidir le bevacizumab éifeachtúlacht an imdhíteiripe a fheabhsú. Dá bhrí sin, is meascán corraitheach é seo d’ailse cheirbheacs, agus táimid ag fanacht go fonnmhar le torthaí an staidéir seo.
In another clinical trial, researchers are studying how two immunotherapy drugs, durvalumab (IMFINZI) and tremelimumab, can be combined with radiation therapy to see if radiation can enhance the immune response.
Chuir dóchas níos mó agus níos mó taighde imdhíteiripe ailse cheirbheacs le hothair ailse cheirbheacs, agus táimid ag tnúth le héifeachtaí cóireála níos fearr.
